Long‐term follow‐up of patients with phenylketonuria receiving tetrahydrobiopterin treatment
- 9 March 2010
- journal article
- research article
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 33 (S3) , 163-169
Abstract
Treatment with tetrahydrobiopterin (BH4), the natural cofactor of phenylalanine hydroxylase (PAH), can reduce blood phenylalanine (Phe) levels in patients with BH4‐responsive phenylketonuria (PKU). A number of studies has reported on the short‐term BH4 treatment of patients with PKU, but long‐term data are lacking. Here, we describe the effects of long‐term treatment with BH4 on 16 patients, who showed a >28% reduction in blood Phe following testing for BH4 overload. The mean dose of BH4 was 16 mg/kg body weight (range 5–36 mg/kg body weight). The mean treatment duration was 56 months (range 24–110 months). Of 16 patients, 14 achieved long‐term Phe control with BH4 treatment, with a mean blood Phe concentration of 321 ± 236 µmol/l. The mean decrease from baseline in blood Phe levels in these 14 patients was 54.6%. Of the seven patients who required continued dietary restriction, Phe intake increased from 200–300 mg/day to 800–1000 mg/day. Factors that may cause fluctuation of Phe levels in BH4‐treated patients include patients’ PAH genotype, Phe intake, changes in protein catabolism or anabolism, and periods of illness or infection.Keywords
This publication has 11 references indexed in Scilit:
- Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuriaAmerican Journal of Medical Genetics Part A, 2008
- Molecular genetics of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiencyHuman Mutation, 2007
- Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled studyThe Lancet, 2007
- Clinical and nutritional evaluation of phenylketonuric patients on tetrahydrobiopterin monotherapyMolecular Genetics and Metabolism, 2005
- Long-term treatment of patients with mild and classical phenylketonuria by tetrahydrobiopterinMolecular Genetics and Metabolism, 2005
- Spanish BH4-responsive phenylalanine hydroxylase-deficient patients: Evolution of seven patients on long-term treatment with tetrahydrobiopterinMolecular Genetics and Metabolism, 2005
- National Institutes of Health Consensus Development Conference Statement: Phenylketonuria: Screening and Management, October 16–18, 2000Pediatrics, 2001
- Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiencyThe Journal of Pediatrics, 1999
- Rationale for the German recommendations for phenylalanine level control in phenylketonuria 1997European Journal of Pediatrics, 1999
- Phenylalanine hydroxylase genotypes, predicted residual enzyme activity and phenotypic parameters of diagnosis and treatment of phenylketonuriaEuropean Journal of Pediatrics, 1996